13F Holdings
中文EN

MTNB Matinas BioPharma Holdings, Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 1582554 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY58.9%
TTM EPS YoY114.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-147.5%
ROA-98.4%
ROIC (approx.)-535.3%
Asset turnover—

Leverage & solvency

Liabilities / assets33.1%
Debt / equity0.00x
Current ratio1.78x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.95x
Accruals ratio-5.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue——$1.10M$3.19M$33,000
R&D expense$85,000$11.43M$14.49M$16.68M$14.58M
SG&A expense$6.88M$8.73M$10.37M$11.10M$10.19M
Operating income-$6.96M-$24.59M-$23.77M-$24.59M-$24.73M
Pretax income-$10.35M-$24.33M-$22.94M——
Income tax—-$80,000———
Net income-$10.35M-$24.25M-$22.94M-$21.00M-$23.28M
EBITDA-$6.93M-$24.23M-$23.38M-$24.25M-$24.49M
EPS (basic)-2.00-4.98-5.28-0.10-0.11
EPS (diluted)-2.00-4.98-5.28-0.10-0.11
Weighted avg. shares (diluted)5.47M4.87M4.35M216.81M210.18M
Balance sheet
Cash & equivalents$4.00M$7.28M$4.79M$6.83M$21.03M
Short-term investments——$8.97M$21.93M$28.59M
Current assets$4.08M$8.03M$15.54M$34.53M$50.99M
PP&E, net$138,000$468,000$1.92M$2.09M$1.54M
Goodwill——$1.34M$1.34M$1.34M
Intangibles$2.26M$2.26M$3.02M$3.02M$3.02M
Total assets$7.21M$12.64M$25.10M$44.82M$61.33M
Current liabilities$1.46M$2.67M$2.62M$4.29M$4.35M
Total liabilities$2.38M$5.05M$5.86M$8.18M$8.83M
Shareholders' equity$4.83M$7.59M$19.25M$36.64M$52.49M
Shares outstanding427,0795.09M4.35M217.26M216.27M
Cash flow statement
Operating cash flow-$7.01M-$15.88M-$15.28M-$19.16M-$15.22M
Capital expenditure——$218,000$892,000$260,000
Free cash flow——-$15.50M-$20.05M-$15.48M
Investing cash flow$335,000$9.21M$13.24M$4.88M$16.77M
Financing cash flow$3.39M$9.17M-$7,000$79,000$6.96M
Depreciation & amortization$32,000$365,000$385,000$337,000$244,000
Stock-based compensation$1.02M$3.19M$4.95M$5.23M$4.29M

Free plan shows the latest 5 periods; Pro shows all 13 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.